Clinical Trials Logo

Inclusion Body Myositis (IBM) clinical trials

View clinical trials related to Inclusion Body Myositis (IBM).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02481453 Completed - Clinical trials for Inclusion Body Myositis (IBM)

Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis

RAPAMI
Start date: July 15, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease. Rapamycin used in organ transplantation blocks the activity of T effector cells, preserves T regulatory cells and induces autophagy (protein degradation), all parameters impaired during IBM. RAPAMI is a prospective, randomised, controlled, double blind, monocentric, phase IIb trial evaluating rapamycine against placebo.